509 Publications Available
March 22, 2019

Review on the mechanisms of regulating oncogenic RAS signaling pathway in cancer and strategies for drugging “undruggable” targets.

March 21, 2019
Cancer Research

Dana-Farber Cancer Institute scientists analyzed data from genome-wide RNAi and CRISPR-Cas9 screens. Results of this study showed the hypoxia-inducing factor, EGLN1, as a preferential and druggable cancer dependency in a subset of cancer cell lines.

March 21, 2019
Cell Chemical Biology

Scientists at the Emory University CTD2 Center developed the High-Throughput immunomodulator Phenotypic (HTiP) screening platform to explore PPI inhibitors, as immunomodulators. This screening identified the Inhibitor of Apoptosis Protein (IAP) as anti-tumor immunity enhancers.

March 18, 2019
Cancer Cell

Bioinformatics analysis of The Cancer Genome Atlas (TCGA) data identifies focal adhesion kinase as a potential therapeutic target for uveal melanoma.

March 15, 2019
Cancer Discovery

Patient-derived in vitro and in vivo model systems discovered novel gene fusion, LAMTOR1-AKT1, as a tumorigenic driver in pediatric epithelioid neoplasm.

March 12, 2019

Integration of genetic and chemical screens identified a synthetic lethal relationship between SMARCB1-deficient cancers and the ubiquitin-proteasome system.

March 07, 2019

Concurrent measurement of single cell expression in tumor cells and tumor-infiltrating lymphocytes revealed novel biological insights of the tumor microenvironment; provides basis for developing novel therapeutic targets in lymphoma.

March 04, 2019
Current Opinion in Genetics & Development
March 04, 2019
Journal for ImmunoTherapy of Cancer

CTD2 scientists at the University of California, San Francisco showed that α-PD-1/α-TGFβ combinatorial therapy could be a potential treatment option for squamous cell carcinomas with high mutational load and form the basis for the clinical trial NCT02947165.

March 01, 2019
Experimental Hematology

Review on using human pluripotent stem cells derived natural killer cells and macrophages as a novel cell-based approach for cancer immunotherapy.